Handling Erythropoietin Resistance with Oxypentifylline
Principal Investigator: Professor David Johnson
Clinical Research Associate: Alicia Morrish (AKTN)
Trial Number: AKTN 06.03
Population: Stage 4/5 CKD patients with moderate to high resistance to ESA
Final recruitment number: 53 (target of 110)
Intervention: 400mg Oxpentifylline versus placebo, daily for four months
Primary outcome: ESA Resistance index at four months
Results: The HERO trial found that Oxpentifylline did not significantly reduce ESA resistance, but did safely increase haemoglobin levels despite a non-specific reduction in ESA dose. Oxypentifylline should be considered a treatment option for patients with ESA-resistant anaemia. Results of the study have been published in Nephrology, the Canadian Journal of Kidney Health and Disease, REDOX Report and Am j Kidney Dis.
Click here to view the Statistical Analysis Plan
Publications:
Read the full publications via the links below.
Click here to read the Main Results Paper
Click here to read the Alkaline phosphatase paper
Click here to read the Methods paper
Click here to read the Oxidative stress substudy
Click here to read the Hepcidin substudy